Consensus document for lipid profile testing and reporting in Spanish clinical laboratories: what parameters should a basic lipid profile include?

  1. Arrobas Velilla, Teresa 116
  2. Guijarro, Carlos 2425
  3. Ruiz, Raquel Campuzano 61415
  4. Piñero, Manuel Rodríguez 3435
  5. Valderrama Marcos, José Francisco 89
  6. Pérez Pérez, Antonio 1011
  7. Botana López, Antonio M. 23
  8. López, Ana Morais 521
  9. García Donaire, José Antonio 1213
  10. Obaya, Juan Carlos 2223
  11. Castilla-Guerra, Luis 1
  12. Carratalá, Vicente Pallares 26272829
  13. Cabello, Isabel Egocheaga 1920
  14. Lazo, Mercedes Salgueira 3233
  15. Castellanos Rodrigo, María Mar 1718
  16. Mostaza Prieto, José María 45
  17. Gómez Doblas, Juan José 67
  18. Buño Soto, Antonio 3031
  1. 1 Hospital Universitario Virgen Macarena
    info
    Hospital Universitario Virgen Macarena

    Sevilla, España

    ROR https://ror.org/016p83279

    Localización xeográfica da organización Hospital Universitario Virgen Macarena
  2. 2 Sociedad Española de Endocrinología y Nutrición
    info
    Sociedad Española de Endocrinología y Nutrición

    Madrid, España

    Localización xeográfica da organización Sociedad Española de Endocrinología y Nutrición
  3. 3 Hospital Universitario Lucus Augusti
    info
    Hospital Universitario Lucus Augusti

    Lugo, España

    ROR https://ror.org/0416des07

    Localización xeográfica da organización Hospital Universitario Lucus Augusti
  4. 4 Sociedad Española de Arteriosclerosis
    info
    Sociedad Española de Arteriosclerosis

    Barcelona, España

    Localización xeográfica da organización Sociedad Española de Arteriosclerosis
  5. 5 Hospital Universitario La Paz
    info
    Hospital Universitario La Paz

    Madrid, España

    ROR https://ror.org/01s1q0w69

    Localización xeográfica da organización Hospital Universitario La Paz
  6. 6 Sociedad Española de Cardiología
    info
    Sociedad Española de Cardiología

    Madrid, España

    Localización xeográfica da organización Sociedad Española de Cardiología
  7. 7 Hospital Universitario Virgen de la Victoria
    info
    Hospital Universitario Virgen de la Victoria

    Málaga, España

    ROR https://ror.org/05xxs2z38

    Localización xeográfica da organización Hospital Universitario Virgen de la Victoria
  8. 8 Spanish Society of Cardiovascular and Endovascular Surgery;
  9. 9 Hospital Regional Universitario de Málaga
    info
    Hospital Regional Universitario de Málaga

    Málaga, España

    ROR https://ror.org/01mqsmm97

    Localización xeográfica da organización Hospital Regional Universitario de Málaga
  10. 10 Sociedad Española de Diabetes
    info
    Sociedad Española de Diabetes

    Madrid, España

    Localización xeográfica da organización Sociedad Española de Diabetes
  11. 11 Hospital de la Santa Creu i Sant Pau
    info
    Hospital de la Santa Creu i Sant Pau

    Barcelona, España

    ROR https://ror.org/059n1d175

    Localización xeográfica da organización Hospital de la Santa Creu i Sant Pau
  12. 12 Sociedad Española de Hipertensión - Liga Española para la lucha contra la HTA
    info
    Sociedad Española de Hipertensión - Liga Española para la lucha contra la HTA

    Madrid, España

    Localización xeográfica da organización Sociedad Española de Hipertensión - Liga Española para la lucha contra la HTA
  13. 13 Hospital Clínico San Carlos de Madrid
    info
    Hospital Clínico San Carlos de Madrid

    Madrid, España

    ROR https://ror.org/04d0ybj29

    Localización xeográfica da organización Hospital Clínico San Carlos de Madrid
  14. 14 Fundación Hospital Alcorcón
    info
    Fundación Hospital Alcorcón

    Alcorcón, España

    ROR https://ror.org/01435q086

    Localización xeográfica da organización Fundación Hospital Alcorcón
  15. 15 Association for Vascular Risk and Cardiac Rehabilitation of the Spanish Society of Cardiology , Madrid , Spain
  16. 16 Spanish Society of Laboratory Medicine (SEQCML);
  17. 17 Sociedad Española de Neurología
    info
    Sociedad Española de Neurología

    Barcelona, España

    Localización xeográfica da organización Sociedad Española de Neurología
  18. 18 Complexo Hospitalario Universitario da Coruña
    info
    Complexo Hospitalario Universitario da Coruña

    La Coruña, España

    ROR https://ror.org/044knj408

    Localización xeográfica da organización Complexo Hospitalario Universitario da Coruña
  19. 19 Spanish Society of General and Family Doctors (SEMG);
  20. 20 Family and Community Medicine , Centro de Salud Isla de Oza, Servicio Madrileño de Salud , Madrid , Spain
  21. 21 Sociedad Española de Gastroenterología, Hepatología y Nutrición Pediátrica
    info
    Sociedad Española de Gastroenterología, Hepatología y Nutrición Pediátrica

    Madrid, España

    Localización xeográfica da organización Sociedad Española de Gastroenterología, Hepatología y Nutrición Pediátrica
  22. 22 Sociedad Española de Medicina Familiar y Comunitaria
    info
    Sociedad Española de Medicina Familiar y Comunitaria

    Barcelona, España

    Localización xeográfica da organización Sociedad Española de Medicina Familiar y Comunitaria
  23. 23 CS La Chopera, Alcobendas , Madrid , Spain
  24. 24 Spanish Society of Arteriosclerosis (SEA);
  25. 25 Unit of Internal Medicine , Hospital Alcorcón Foundation University Hospital, Rey Juan Carlos University , Madrid , Spain
  26. 26 Hospital Virgen Macarena, PCDV Departamento de Medicina , University of Seville , Sevilla , Spain
  27. 27 Spanish Society of Primary Care Physicians (SEMERGEN);
  28. 28 Unit of Health Surveillance, Unión de Mutuas;
  29. 29 Department of Medicine , Universitat Jaume I, Castellón , Castellón , Spain
  30. 30 Spanish Society of Laboratory Medicine (SEQCML);
  31. 31 Service of Clinical Biochemistry , La Paz University Hospital , Madrid , Spain
  32. 32 Spanish Society of Nephrology (SEN);
  33. 33 Unit of Nephrology , Virgen Macarena University Hospital , Seville , Spain
  34. 34 Spanish Society of Angiology and Vascular Surgery (SEACV),;
  35. 35 Cross-center Cádiz-Jerez Unit of Angiology and Vascular Surgery , Puerta del Mar University Hospital , Cádiz , Spain
Mostrar afiliacións +
Revista:
Advances in Laboratory Medicine / Avances en Medicina de Laboratorio

ISSN: 2628-491X

Ano de publicación: 2023

Volume: 4

Número: 2

Páxinas: 138-156

Tipo: Artigo

DOI: 10.1515/ALMED-2023-0047 GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Advances in Laboratory Medicine / Avances en Medicina de Laboratorio

Resumo

Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice. There is a great heterogeneity in the reports of lipid metabolism from Spanish clinical laboratories, which may contribute to its poor control. For this reason, a working group of the main scientific societies involved in the care of patients at vascular risk, has prepared this document with a consensus proposal on the determination of the basic lipid profile in cardiovascular prevention, recommendations for its realization and unification of criteria to incorporate the lipid control goals appropriate to the vascular risk of the patients in the laboratory reports.Keywords: apolipoprotein B; biochemistry; cardiovascular diseases; cholesterol; consensus; lipoprotein (a).

Referencias bibliográficas

  • Roth, GA, Abate, D, Abate, KH, Abay, SM, Abbafati, C, Abbasi, N, et al.. GBD 2017 Causes of Death Collaborators Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond Engl 2018;392:1736–88. https://doi.org/10.1016/S0140-6736(18)32203-7.
  • INE Defunciones por causas (lista reducida) por sexo y grupos de edad(7947). INE Available from: https://www.ine.es/jaxiT3/Datos.htm?t=7947#!tabs-tabla [accedido 16 febrero 2022].
  • Borén, J, Chapman, MJ, Krauss, RM, Packard, CJ, Bentzon, JF, Binder, CJ, et al.. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020;41:2313–30. https://doi.org/10.1093/eurheartj/ehz962.
  • Royo Bordonada, MÁ, Lobos Bejarano, JM, Millán Núñez-Cortés, J, Villar Álvarez, F, Brotons Cuixart, C, Camafort Babkowski, M, et al.. Dislipidemias: un reto pendiente en prevención cardiovascular. Documento de consenso CEIPC/SEA. Med Clínica 2011;137:30.e1–13, https://doi.org/10.1016/j.medcli.2011.02.008.
  • De Backer, G, Jankowski, P, Kotseva, K, Mirrakhimov, E, Reiner, Ž, Rydén, L, et al.. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019;285:135–46. https://doi.org/10.1016/j.atherosclerosis.2019.03.014.
  • Ray, KK, Molemans, B, Schoonen, WM, Giovas, P, Bray, S, Kiru, G, et al.. EU-wide cross- sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol 2021;28:1279–89. https://doi.org/10.1093/eurjpc/zwaa047.
  • González-Juanatey, JR, Millán, J, Alegría, E, Guijarro, C, Lozano, JV, Vitale, GC. Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain study. Rev Esp Cardiol Engl Ed 2011;64:286–94. https://doi.org/10.1016/j.rec.2010.10.030.
  • Robinson, JG, Huijgen, R, Ray, K, Persons, J, Kastelein, JJP, Pencina, MJ. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol 2016;68:2412–21. https://doi.org/10.1016/j.jacc.2016.09.928.
  • Visseren, FLJ, Mach, F, Smulders, YM, Carballo, D, Koskinas, KC, Bäck, M, et al.. ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2021;42:3227–337. https://doi.org/10.1093/eurheartj/ehab484.
  • Visseren, LJF, Mach, F, Smulders, MY, Carballo, D, Koskinas, CK, Bäck, M, et al.. Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica: con la contribución especial de la European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol 2022;75:429.e1–104. https://doi.org/10.1016/j.recesp.2021.10.016.
  • Palacio-Portilla, EJ, Roquer, J, Amaro, S, Arenillas, JF, Ayo-Martín, O, Castellanos, M, et al.. Dislipidemias y prevención del ictus: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología. Neurología. 2022;37:61–72. https://doi.org/10.1016/j.nrl.2020.07.027.
  • Mostaza, JM, Pintó, X, Armario, P, Masana, L, Real, JT, Valdivielso, P, et al.. Estándares SEA 2022 para el control global del riesgo cardiovascular. Clínica E Investig En Arterioscler 2022;34:130–79. https://doi.org/10.1016/j.arteri.2021.11.003.
  • Armario, P, Brotons, C, Elosua, R, Alonso de Leciñana, M, Castro, A, Clarà, A, et al.. Statement of the Spanish interdisciplinary vascular prevention committee on the updated European cardiovascular prevention guidelines. Clin E Investig En Arterioscler Publicacion Soc Espanola Arterioscler 2021;33:85–107. https://doi.org/10.1016/j.arteri.2020.11.004.
  • Pedro-Botet, J, Rodríguez-Padial, L, Brotons, C, Esteban-Salán, M, García-Lerín, A, Pintó, X, et al.. Homogeneización de los valores del perfil lipídico. Clínica E Investig En Arterioscler 2018;30:36–48. https://doi.org/10.1016/j.arteri.2017.12.001.
  • Pedro-Botet, J, Rodríguez-Padial, L, Brotons, C, Esteban-Salán, M, García-Lerín, A, Pintó, X, et al.. El informe analítico ideal del perfil lipídico. Necesidad de un consenso. Rev Esp Cardiol 2018;71:512–4. https://doi.org/10.1016/j.recesp.2018.01.004.
  • Wright, IS. Correct levels of serum cholesterol: average vs. normal vs. optimal. J Am Med Assoc 1976;236:261–2. https://doi.org/10.1001/jama.1976.03270030015018.
  • Mach, F, Baigent, C, Catapano, AL, Koskinas, KC, Casula, M, Badimon, L, et al.. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455.
  • Cooper, GR, Myers, GL, Smith, SJ, Schlant, RC. Blood lipid measurements: variations and practical utility. J Am Med Assoc 1992;267:1652–60. https://doi.org/10.1001/jama.1992.03480120090039.
  • Bays, HE, Jones, PH, Orringer, CE, Brown, WV, Jacobson, TA. National lipid association annual summary of clinical lipidology 2016. J Clin Lipidol. 2016;10:S1-43, https://doi.org/10.1016/j.jacl.2015.08.002.
  • Herink, M, Ito, MK. Medication induced changes in lipid and lipoproteins. In: Feingold, KR, Anawalt, B, Boyce, A, Chrousos, G, de, Herder WW, Dhatariya, K, et al.. editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.
  • Khovidhunkit, W, Kim, M-S, Memon, RA, Shigenaga, JK, Moser, AH, Feingold, KR, et al.. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169–96. https://doi.org/10.1194/jlr.R300019-JLR200.
  • Feingold, KR, Grunfeld, C. The effect of inflammation and infection on lipids and lipoproteins. In: Feingold, KR, Anawalt, B, Boyce, Ade, Herder WW Dhatariya, K, et al.. editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.
  • van Leeuwen, HJ, Heezius, ECJM, Dallinga, GM, van Strijp, JAG, Verhoef, J, van Kessel, KPM. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003;31:1359–66. https://doi.org/10.1097/01.CCM.0000059724.08290.51.
  • Páez-Guillán, E-M, Campos-Franco, J, Alende, R, Garitaonaindía, Y, González-Quintela, A. Transient hypertriglyceridemia: a common finding during Epstein-Barr virus-induced infectious mononucleosis. Lipids Health Dis 2021;20:177. https://doi.org/10.1186/s12944-021-01603-9.
  • Shrivastava, AK, Singh, HV, Raizada, A, Singh, SK. Serial measurement of lipid profile and inflammatory markers in patients with acute myocardial infarction. EXCLI J 2015;14:517–26. https://doi.org/10.17179/excli2014-671.
  • Wattanasuwan, N, Khan, IA, Gowda, RM, Vasavada, BC, Sacchi, TJ. Effect of acute myocardial infarction on cholesterol ratios. Chest 2001;120:1196–9. https://doi.org/10.1378/chest.120.4.1196.
  • Rosenson, RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993;22:933–40. https://doi.org/10.1016/0735-1097(93)90213-k.
  • Enkhmaa, B, Anuurad, E, Berglund, L. Lipoprotein (a): impact by thnicity and environmental and medical conditions. J Lipid Res 2016;57:1111–25. https://doi.org/10.1194/jlr.R051904.
  • Langsted, A, Kamstrup, PR, Nordestgaard, BG. Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis 2014;234:95–101. https://doi.org/10.1016/j.atherosclerosis.2014.01.049.
  • Nordestgaard, BG, Langsted, A, Mora, S, Kolovou, G, Baum, H, Bruckert, E, et al.. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016;37:1944–58. https://doi.org/10.1093/eurheartj/ehw152.
  • Mora, S, Rifai, N, Buring, JE, Ridker, PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008;118:993–1001. https://doi.org/10.1161/CIRCULATIONAHA.108.777334.
  • Martin, SS, Blaha, MJ, Elshazly, MB, Toth, PP, Kwiterovich, PO, Blumenthal, RS, et al.. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. J Am Med Assoc 2013;310:2061–8. https://doi.org/10.1001/jama.2013.280532.
  • Wilson, PWF, Jacobson, TA, Martin, SS, Jackson, EJ, Le, N-A, Davidson, MH, et al.. Lipid measurements in the management of cardiovascular diseases: practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol 2021;15:629–48. https://doi.org/10.1016/j.jacl.2021.09.046.
  • Martin, SS, Blaha, MJ, Elshazly, MB, Brinton, EA, Toth, PP, McEvoy, JW, et al.. Friedewald- estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol 2013;62:732–9. https://doi.org/10.1016/j.jacc.2013.01.079.
  • Sniderman, AD, Williams, K, Contois, JH, Monroe, HM, McQueen, MJ, De Graaf, J, et al.. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk. Circ Cardiovasc Qual OuTgomes 2011;4:337–45. https://doi.org/10.1161/CIRCOUTgOMES.110.959247.
  • Nordestgaard, BG, Langlois, MR, Langsted, A, Chapman, MJ, Aakre, KM, Baum, H, et al.. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Atherosclerosis 2020;294:46–61. https://doi.org/10.1016/j.atherosclerosis.2019.12.005.
  • Arnett, DK, Blumenthal, RS, Albert, MA, Buroker, AB, Goldberger, ZD, Hahn, EJ, et al.. ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation 2019;140:e596-600.
  • Grundy, SM, Stone, NJ, Bailey, AL, Beam, C, BirTgher, KK, Blumenthal, RS, et al.. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of Cardiology/American heart association Task Force on clinical practice guidelines. Circulation 2019;139:e1082–143. https://doi.org/10.1161/CIR.0000000000000625.
  • Pearson, GJ, Thanassoulis, G, Anderson, TJ, Barry, AR, Couture, P, Dayan, N, et al.. Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol 2021;S0828–282X:00165–3. https://doi.org/10.1016/j.cjca.2021.03.016.
  • Langlois, MR, Nordestgaard, BG, Langsted, A, Chapman, MJ, Aakre, KM, Baum, H, et al.. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med 2020;58:496–517. https://doi.org/10.1515/cclm-2019-1253.
  • Marston, NA, Giugliano, RP, Melloni, GEM, Park, J-G, Morrill, V, Blazing, MA, et al.. Association of apolipoprotein B–containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content. JAMA Cardiol 2022;7:250–6. https://doi.org/10.1001/jamacardio.2021.5083.
  • SCORE2 working group and ESC Cardiovascular risk collaboration SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439–54, https://doi.org/10.1093/eurheartj/ehab309.
  • SCORE2-OP working group and ESC Cardiovascular risk collaboration SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 2021;42:2455–67, https://doi.org/10.1093/eurheartj/ehab312.
  • Di Angelantonio, E, Sarwar, N, Perry, P, Kaptoge, S, Ray, KK, Thompson, A, et al., Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. J Am Med Assoc 2009;302:1993–2000. https://doi.org/10.1001/jama.2009.1619.
  • Richardson, T, Sanderson, E, Palmer, TM, Ala-Korpela, M, Ference, BA, Davey Smith, G, et al.. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. Plos Med 2020;17. https://doi.org/10.1371/journal.pmed.1003062.
  • Pintó, X, Masana, L, Civeira, F, Real, J, Ibarretxe, D, Candas, B, et al.. Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®). Clin E Investig En Arterioscler Publicacion Of Soc Espanola Arterioscler 2020;32:219–29. https://doi.org/10.1016/j.arteri.2020.04.004.
  • WHO Human Genetics Programme Familial hypercholesterolaemia (FH) : report of a second WHO consultation, Geneva: World Health Organization; 1999.
  • Paquette, M, Bernard, S, Blank, D, Paré, G, Baass, A. A simplified diagnosis algorithm for dysbetalipoproteinemia. J Clin Lipidol 2020;14:431–7. https://doi.org/10.1016/j.jacl.2020.06.004.
  • Wilson, DP, Jacobson, TA, Jones, PH, Koschinsky, ML, McNeal, CJ, Nordestgaard, BG, et al.. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2019;13:374–92. https://doi.org/10.1016/j.jacl.2019.04.010.
  • Reyes-Soffer, G, Ginsberg, HN, Berglund, L, Duell, PB, Heffron, SP, Kamstrup, PR, et al.. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol 2021;42:e48-60. https://doi.org/10.1161/ATV.0000000000000147.
  • Cegla, J, Neely, RDG, France, M, Ferns, G, Byrne, CD, Halcox, J, et al.. HEART UK consensus statement on Lipoprotein(a): a call to action. Atherosclerosis 2019;291:62–70. https://doi.org/10.1016/j.atherosclerosis.2019.10.011.
  • Kronenberg, F, Mora, S, Stroes, ESG, Ference, BA, Arsenault, BJ, Berglund, L, et al.. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43:3925–46. https://doi.org/10.1093/eurheartj/ehac361.
  • Burgess, S, Ference, BA, Staley, JR, Freitag, DF, Mason, AM, Nielsen, SF, et al.. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)- lowering therapies: a mendelian randomization analysis. JAMA Cardiol 2018;3:619–27. https://doi.org/10.1001/jamacardio.2018.1470.
  • Langsted, A, Kamstrup, PR, Benn, M, Tybjærg-Hansen, A, Nordestgaard, BG. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol 2016;4:577–87. https://doi.org/10.1016/S2213-8587(16)30042-0.
  • Ascaso, JF, Civeira, F, Guijarro, C, López Miranda, J, Masana, L, Mostaza, JM, et al.. Indicaciones de los inhibidores de proproteína convertasa subtilisina kexina 9 (PCSK9) en la práctica clínica. Recomendaciones de la Spanish Society of Arteriosclerosis (SEA) 2019. Clin E Investig En Arterioscler Publicacion Of Soc Espanola Arterioscler 2019;31:128–39. https://doi.org/10.1016/j.arteri.2019.04.002.
  • Conrad, N, Verbeke, G, Molenberghs, G, Goetschalckx, L, Callender, T, Cambridge, G, et al.. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 2022;400:733–43. https://doi.org/10.1016/S0140-6736(22)01349-6.
  • Moulin, P, Dufour, R, Averna, M, Arca, M, Cefalù, AB, Noto, D, et al.. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an «FCS score». Atherosclerosis 2018;275:265–72. https://doi.org/10.1016/j.atherosclerosis.2018.06.814.